Which coronavirus vaccine is the best?

Getty Images

Johnson & Johnson reported that its coronavirus vaccine has entered the final stage of testing.

The global race to find a cure for it coronavirus continues in its frenzied dispute and this Wednesday the giant Johnson & Johnson (J&J) has announced good news, as its vaccine has entered the last stage of testing.

Like Moderna, Pfizer and AstraZeneca, the vaccine developed by the Belgian laboratory Janssen Pharmaceutical Companies, part of the Johnson & Johnson group of companies, travel the final test stretch thanks to the “Operation Speed ​​of Light” program, launched by the President’s administration Donald Trump after a multi-million dollar investment.

According to what he publishes The Washington Post, the J&J antidote is already evaluated in 60 thousand Americans, while it will also be tested in Argentina and other Latin American countries and the world.

“The Company is committed to bringing an affordable vaccine to the non-profit public for use in the face of the pandemic emergency and anticipates that the first batches of the COVID-19 vaccine will be available for authorization for emergency use in early 2021. , if it proves safe and effective “, J&J advances in the notice disseminated on its official page and on social networks.

For his part Alex Gorsky, president and director of the pharmaceutical conglomerate, shows expectations about the achievements obtained in recent months and emphasizes that achieving a cure against the coronavirus is the absolute priority.

“As the world’s largest healthcare company, we are bringing our best scientific minds and rigorous safety standards, in collaboration with regulators, to accelerate the fight against this pandemic. This fundamental milestone demonstrates our efforts towards a COVID-19 vaccine that are based on collaboration and deep commitment to a robust scientific process, ”Gorsky remarks.

As Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson, notes: “We greatly value the collaboration and support of our scientific partners and global health authorities as our global team of experts works tirelessly on developing of the vaccine and expands our production capacity with the aim of delivering a vaccine for emergency use authorization in early 2021 ”.

Advantage

Although the vaccines that Moderna, Pfizer and AstraZeneca have been developing entered phase 3 testing earlier, the one developed by Janssen has some specific advantages that could be decisive in the future.

While the other three samples being tested in the United States require a second injection three to four weeks after the first, the Belgian laboratory is initially testing with a single dose.

On the other hand, this vaccine promoted by J&J will be shipped frozen but can also be stored in liquid form at refrigerator temperature for three months. Quite the opposite of two of its competitors, since they must be frozen or kept at freezing temperatures until shortly before use.

“A single injection vaccine, if it is safe and effective, will have substantial logistical advantages in controlling the global pandemic,” argues Dan Barouch, director of the Virology and Vaccine Research Center at Beth Israel Deaconess Medical Center in Boston and associate. with J&J to develop the vaccine, in statements reported by The Washington Post.

Third and last, the J&J vaccine is the second to use a viral vector approach, taking a harmless virus and inserting into it a gene that contains the blueprint for a distinctive part of the new coronavirus.

READ MORE: Donald Trump lashes out at China for the coronavirus: What punishment is the US president asking for?

Follow Now Same on Instagram


.

China runs on Coronavirus vaccine: “Test goes smoothly”

AGI – The Chinese vaccine against Covid-19 could be available to the public as early as next November. This was stated by the bio-security expert of the China Center of Disease Control and Prevention Wu Guizhen, during an interview with the state television station China Central Television.

The vaccine may be available “in November or December”, Wu said, “because Phase 3 of clinical trials is currently running smoothly.” Wu herself then stated that she had undergone a vaccine test, without specifying which one, last April and “in the last few months I felt very well”, she continued, without experiencing pain locally.

.

After being stopped, the Corona vaccine trial from Oxford was resumed

KOMPAS.com – The pharmaceutical giant AstraZeneca and Oxford University says it has resumed vaccine trials Covid-19 on Saturday (13/9/2020), after receiving approval from British regulators.

“Clinical trials for vaccines corona virus AstraZeneca Oxfor, AZD1222, has been resumed in the UK following confirmation from the Medicines Health Regulatory Authority (MHRA) that it is safe to do so, “the company said in a statement. AFP, Saturday (12/9/2020).

On Wednesday (9/9/2020), AstraZeneca announced that it had suspended vaccine trials corona virus after a volunteer fell ill.

An independent committee designed to review the safety of vaccine trials has concluded its investigation and recommended that the MHRA continue trials.

The Oxford University has also confirmed the trial vaccine corona virus resumed.

Also read: Volunteers Fall Sick, Oxford’s Covid-19 Vaccine Trials Suspended

“In a large trial like this one, it is expected that some participants will become unwell and each case must be carefully evaluated to ensure a careful safety assessment,” Oxford said in a statement.

Although it was stopped, AstraZeneca hopes the vaccine will be available at the end of this year or early next year.

However, many pharmaceutical companies, including AstraZeneca and scientists, expressed concern about political pressure to release a vaccine immediately.

Lose control

The AstraZeneca vaccine candidate is one of nine vaccines worldwide currently in Phase 3 trials in humans.

In the United States, companies began enrolling 30,000 volunteers at several locations on August 31, 2020.

.

As many as 50 countries have expressed interest in the Russian coronavirus vaccine

Russia is negotiating with 50 countries to supply a coronavirus vaccine developed at the Nikolai Gamaleji Institute of Epidemiological and Microbiological Research in cooperation with the Russian Direct Investment Fund (RDIF) and the Ministry of Defense. The head of the fund, Kirill Dmitrijev, spoke about this on the broadcast of the First Channel station.

In this context, Dmitry noted that since Russia can produce “only a certain amount” of this vaccines, the number of countries with which RDIF cooperates is also limited.

“We work with 50 countries. We are now focusing mainly on 20 of them, in which we have made great progress, “he said.

The head of RDIF also added that in many countries they are already starting clinical trials of the Russian vaccine. Regulators’ approval could then be obtained in October or November.

“That is why we are focusing on those countries that are interested in the rapid approval of the Russian vaccine and that are showing considerable interest in partnering with Russia,” he explained.

Russian vaccine Sputnik V

At the beginning of August, the Ministry of Health of the Russian Federation registered the first vaccine against covidu-19 developed by experts from the Nikolai Gamaleji Institute of Epidemiological and Microbiological Research with the support of the Russian Direct Investment Fund. It was named Sputnik V and its production has already begun.

The safety of the vaccine was confirmed in a two-phase study involving 38 volunteers. It was found that all those who received the vaccine developed immunity to the infection. Alexandr Ginzburg, director of the NF Gamaleji Institute, said that the use of the vaccine among citizens would be allowed after the third phase of research into the product.

Many other countries have already expressed interest in the vaccine, but according to Russia’s health minister, enough benefits must be made for the internal market first. Those who work with sick covid-19 and people from risk groups will be the first to be vaccinated. Mass vaccination in Russia should start in October.

According to information from the State Register of Medicines, the product will be manufactured in the form of a solution for intramuscular administration. Vaccination is planned to carry out in two stages: first with component I and three weeks later with component II. According to the Russian Ministry of Health, this double scheme will allow the creation of long-term immunity for up to two years.

Recall also that this week was deleted the first dose of the vaccine and the third phase of clinical trials began. According to the Minister of Health Mikhail Muraško, more than 30,000 volunteers have already been gathered. A new format has been developed to monitor their health, including a mobile application that allows direct contact between the patient and the vaccine developer.

.

Wow, Indonesia is experiencing the biggest decline in public confidence in the world in vaccines

Source: Reuters | Editor: SS Kurniawan

KONTAN.CO.ID – LONDON. Indonesia is experiencing one of the world’s largest declines in public confidence in vaccines. This is the result of a global vaccine confidence study conducted by British researchers.

According to a study that charted trends in vaccine confidence in 149 countries between 2015 and 2019, some of the decline in public confidence in Indonesia was triggered by questioning the measles, mumps and rubella vaccines, as well as the promotion of natural alternatives to vaccines.

Global vaccine confidence studies show that political polarization and online misinformation threaten vaccination programs around the world, with public trust shifting and highly variable between countries.

The study found that skepticism about vaccine safety tends to grow alongside political instability and religious extremism.

Also Read: This is the lack of the Covid-19 Sinovac vaccine from China according to Unpad researchers

“It is very important that with the threat of new and emerging diseases such as the COVID-19 pandemic, we are regularly monitoring public attitudes,” said Heidi Larson, professor at the London School of Hygiene & Tropical Medicine who led the research, as quoted. Reuters.

“Perceptions about vaccines are much more unstable than before,” he said. “Overall, there’s a lot of belief in the world about vaccines. But don’t take it lightly. Confidence goes up and down, it varies a lot.”

Published in the medical journal Lancet, Larson’s findings are based on data from more than 284,000 adults who were asked in 2019 whether they saw a vaccine as important, safe and effective.

Larson said, with drugmakers and researchers around the world racing to develop a vaccine against the Covid-19 pandemic, governments must now be extra vigilant in assessing public confidence in vaccines and responding to concerns quickly.

Also Read: AstraZeneca stops testing for the corona vaccine, WHO: This is a wake-up call



.

Corona Virus and Blood Thinning Trials in Covid-19 Patients … Page all

KOMPAS.com – National Institutes of Health ( NIH) is known to have launched two of three final stage clinical trials to test the effectiveness and safety of various types of blood thinners in treating Covid-19 patients in adults.

The three trials were run under the US government’s Operation Warp Speed ​​program, with the aim of accelerating the development, manufacture and distribution of vaccines or drugs against the coronavirus.

For additional information, blood clots throughout the body of a person with Covid-19 are one of the many life-threatening effects.

Also read: Update on Covid-19 Vaccines Around the World, from Russia to England

Blood clots can cause other complications such as heart attack, stroke, and blockage of blood vessels in the lungs.

“Currently there is no standard of care for anticoagulation in hospitalized Covid-19 patients, and clinical evidence is urgently needed for practical guidance,” said NIH Director Francis Collins. Reuters, Friday (11/9/2020).

Researchers started separate trials testing blood thinners in hospitalized Covid-19 patients and people with Covid-19 who had not been hospitalized.

Also read: List of Red Zones Covid-19 in Indonesia, Bali with the most number of 8 districts / cities

Low dosage

AFP / NOEL CELIS The Covid-19 vaccine candidate made by Sinovac Biotech was on display at the China International Fair for Trade in Services (CIFTIS) in Beijing, Sunday (6/9/2020).

People with Covid-19 who have not been hospitalized get a low dose or therapeutic injection of a placebo, aspirin, or Eliquis blood thinner, Bristol-Myers Squibb Co and Pfizer Inc.

Meanwhile, hospitalized Covid-19 patients receive various doses of hepari as a test of the safety and effectiveness of generic blood thinners in preventing blood clots.

The third trial that will begin will focus on Covid-19 patients who have been discharged from the hospital after receiving treatment.

The patient to be tested is in moderate to severe condition.

Also read: High Covid-19 Cases in Indonesia, What Are the Conditions in Southeast Asia?

Launching worldometers, Friday (11/9/2020) at 06.45 WIB, the corona virus has infected 28,312,986 people globally, with 20,325,634 people having recovered.

The number of deaths worldwide reached 913,077 cases.

Here are five countries in the world with the most cases:

1. United States

Illustration of corona virus quarantine, Covid-19Shutterstock Illustration of corona virus quarantine, Covid-19

The United States is a country that reports the most cases of infection in the world.

It was recorded that positive cases of the corona virus in this country reached 6,585,288 cases, with 35,936 new cases within 24 hours.

The highest number of deaths from the new coronavirus also occurred in the US, where 196,132 people were declared dead.

Meanwhile, a country with a population of 331,266,944 people reported that 3,875,666 cases of infection had been declared recovered.

Also read: Obesity and the High Death Rate from Corona Virus in the US …

2. India

India is in the second position of the country with the most cases of corona virus infection.

A total of 4,559,725 positive confirmed cases were reported, of which 3,539,983 had recovered.

This country with a population of 212,764,278 people has reported 76,304 deaths due to the corona virus.

Also read: When Indian PM Promotes Yoga to Fight Corona Virus …

3. Brazil

Brazil is in third place with 4,239,763 infections, with an additional 40,431 new cases in the past day.

The country, with a population of 1,381,826,521 people, has so far recorded 129,575 deaths.

Of the total cases of infection, 3,497,337 people have been declared cured.

4. Russia

In fourth place, Russia reported 1,046,370 positive cases of corona virus infection that occurred in its country, with the addition of 5,363 new cases.

Of the total confirmed cases of exposure to the virus, as many as 862,373 people have been declared cured and 18,263 others have died.

The country has a population of 145,943,139 people.

5. Peru

Peru is the fifth country in the world with 710,067 cases of infection.

This country with a population of 33,050,211 people has recorded that 544,745 cases have recovered.

The corona virus that caused Covid-19 has killed 30,344 people in Peru.

Also read: Questioning the High Covid-19 Death Rate in East Java …


KOMPAS.com/Akbar Bhayu Tamtomo
Infographic: Pandemic Covid-19. Meaning of the Red, Orange, Yellow and Green Zones

.

extremely unlikely to be ready, says exFDA – CNN

(CNN) — It is unlikely that U.S have a COVID-19 vaccine available for widespread use this year, Dr. Scott Gottlieb, former commissioner of the US Food and Drug Administration, said on CBS’s Face the Nation on Sunday.

“The probability that we will have a vaccine for widespread use in 2020 is extremely low. I think we should think of that as an event in much of 2021, and if we have a vaccine available in 2020, it is likely to be used in a much more specific way, almost in a therapeutic sense, to protect very high-risk populations. “Gottlieb told CBS host John Dickerson.

LOOK: Putin’s vaccine meets opposition with frontline workers in Russia

“In terms of thinking about the vaccine, at least as it relates to this year, in 2020, fall and winter, I think that if there is a vaccine available, it is likely to be a very phased introduction of the vaccine under a use authorization. emergency, where there will be a lot of data collection on the use of that vaccine, “Gottlieb said.

«And it will only be very select groups of people who have a very high risk of contracting the coronavirus because of what they do. For example, healthcare workers, or a very high risk of a poor outcome, think of people, for example in a nursing home, ”said Gottlieb.

Bolsonaro will wait for another opinion to approve a vaccine in Brazil 0:57

“So you can almost think that the vaccine is used in a therapeutic sense to try to protect very high-risk populations, and not in the way that we traditionally think of a vaccine in terms of trying to provide background immunity. wide in a population and really quell an epidemic, “he added.

LOOK: Good news in the fight against coronavirus: possible treatments, vaccines and findings

.

The Government is Ready to Distribute Free Covid-19 Vaccines to Poor Citizens

Freepik

The Government is Ready to Distribute Free Covid-19 Vaccines to Poor Citizens

NOVA.id – In the middle of testing coronavirus vaccine, the government is currently preparing a vaccine scheme for the community.

So far the government has 2 routes, namely independent and government assistance.

For standalone vaccines, the price of vaccines depends on the respective sellers.

Also Read: Entering the Trial Phase, the Minister of BUMN Leaks the Selling Price Range of Corona Virus Vaccines

Meanwhile, for people who cannot afford it, the government will provide vaccines for free.

For those who will get the free corona vaccine, the data will be taken from the data of participants receiving contribution assistance (PBI) for the Health Social Security Administration (BPJS).

Head of Public Relations of BPJS Kesehatan, M. Iqbal Anas Ma’ruf, said that in principle, BPJS Kesehatan is ready to implement policies set by the government.

Also Read: As a Clinical Trial Volunteer for Corona Virus Vaccine, Ridwan Kamil met his mother and asked for advice


Featured Video


More complete and in-depth news is available in the NOVA Tabloid. It’s not a hassle to buy, really.

Friends of NOVA can choose to subscribe at Grid Store, or read the electronic version (e-magz) at Gramedia.com, MyEdisi, or Majalah.id.

PROMOTED CONTENT

.

Good News for All Indonesians, Red and White Vaccine Targeted …

Grid.ID – The high number of corona virus cases (Covid-19), making all countries worry.

Therefore, they started making a corona virus vaccine.

One of them is Indonesia.

According to the Head of the Institute for Molecular Biology Eijkman Institute, Amin Soebandrio, the development of the Red and White vaccine is currently ongoing.

Also Read: Previously, enemies, now friends, had threatened each other to fight, suddenly China and Taiwan were united and wanted to attack Japan on a large scale, what happened?

He said, the vaccine development process for Covid-19 it’s 50 percent already.

“It’s 50 percent, we just have to wait for the recombinant protein from the expression system using mammalian cells,” said Amin on Friday (4/9/2020).

Amin hopes that in the next two to three months Eijkman can carry out a preclinical test of the Red and White vaccine on animals developed with a recombinant protein subunit platform.

“It is expected to be completed early next year,” said Amin.

Regarding the progress of the vaccine development process, Amin explained that at this time Eijkman Institute can already amplify the target gene from the part of the SARS-CoV-2 virus that causes it Covid-19.

Next page…







PROMOTED CONTENT

.

Coronavirus vaccine before the US elections? – CNN

(CNN) — The Centers for Disease Control and Prevention U.S have asked states to prepare to distribute a vaccine against the coronavirus no later than next month. Pfizer’s CEO says he thinks his company may have enough data to apply for clearance from the US Food and Drug Administration (FDA).

And officials within the FDA have told CNN that Trump He has consistently pushed agencies to speed up his vaccine development schedule so that he can have a medical victory on Election Day.

Is it really possible that we can have a coronavirus vaccine by November?

Pressure in the US for a vaccine before the election 1:04

Doctors who are conducting clinical trials would know better, and don’t believe it.

“Do the simple math,” said Dr. Larry Corey of the Fred Hutchinson Cancer Research Center in Seattle, who leads the team that coordinates clinical trials for federally supported coronavirus vaccines in the US.

“We designed the test to hit 130,140 endpoints seven months after starting the test,” Corey told CNN. “The first started in mid-July.”

The “endpoints” are coronavirus infections. What Corey is saying is that the trials are designed to continue until 140 to 150 people contract the coronavirus. The researchers would seek to see if the people who received the actual vaccine were less likely to be among those infected.

But if you add seven months to July, you get February.

That does not mean that it is impossible to have an answer before then. If one of the vaccines being tested is very effective and there is a high rate of infection among people who voluntarily participate in the trials, it is possible that many people who received placebo injections will quickly become infected. “If you had a highly effective vaccine, you might find it five months after designing the trial,” said Corey.

But if you add five months to July, you have December.

That still does not bring us to October.

This is how they plan to distribute the coronavirus vaccine 6:15

And there are other obstacles. Dr. Paul Offit, director of the Center for Vaccine Education at Children’s Hospital of Philadelphia and a member of the Food and Drug Administration’s Advisory Committee on Vaccines and Related Biologics, said that most of the Phase 3 trials that are underway are underway they now aim to enroll 30,000 people each. That’s because the people who designed the trials believe that it will take that many volunteers to be able to observe 140 or 150 infections.

None are complete yet, so it is already September and many, if not most, of the volunteers have yet to receive their first dose.

All vaccines in advanced Phase 3 trials require two doses, administered one month apart. Therefore, people who received their first dose in August cannot receive a second dose until September. And those who get vaccines this month won’t get their second dose until October.

“So you have to wait two weeks after the second dose to really have full immunity,” Offit told CNN.

A highly unlikely schedule, though not impossible.

So why is the administration talking about results in November or even October?

“It’s highly unlikely, but theoretically possible without doing anything nefarious,” said Dr. Ann Falsey, a professor at the University of Rochester School of Medicine in New York, who coordinates the clinical trial of the coronavirus vaccine there. by AstraZeneca.

For example, if the virus spreads quickly, that would generate a large amount of data, very fast. “Unfortunately, there can be a real access point and there can be a lot of activity,” Falsey told CNN.

And if one of the vaccines being tested is very effective, it will quickly become apparent. People in the placebo group will be infected at a much higher rate than people who received the actual vaccine.

“Then perhaps you will arrive at a definitive answer sooner than you thought,” he said. “That would be unlikely,” he added.

FDA Commissioner Issues Vaccine Warning 0:43

Offit agreed. The trials are not designed to detect mild or asymptomatic infections, Offit said. “The clinical endpoint is severe disease,” he said. That makes it even less likely that the tests will produce a lot of surprise data ahead of schedule.

And the FDA has already told companies that a vaccine must be at least 50% effective to be considered. That means you will have to reduce the risk of death or serious illness by 50%.

Even if the volunteers are at a virus hotspot, Offit said, they will have been advised to be careful. It is an ethical requirement of trials to warn volunteers about the risks of becoming infected. “People are being told to wear face masks and practice social distancing,” he said.

You’re not telling them to go to a maskless motorcycle convention in South Dakota. You want them to protect themselves.

FDA Can’t Move Faster Than Data

Typically, it takes the FDA a year to approve a vaccine after all the Phase 3 data is submitted, Offit said. An expedited process would take 10 months.

In the event of a pandemic, that process accelerates, and Operation Warp Speed ​​has been executing other necessary steps in parallel with clinical trials, helping companies start manufacturing vaccines even before trials end and ordering syringes and other teams now instead of waiting for the trials to finish, so the FDA is ready to act much, much sooner.

These are the steps for the vaccine against covid-19 3:32

But the only way there would be enough data to advance one of the vaccines in line for FDA emergency use authorization would be if one or more of the trials came up with a surprising amount of data very, very quickly.

Pfizer Chairman and CEO Dr. Albert Bourla believes that could happen. He said his company’s phase 3 clinical trial of the COVID-19 vaccine has enrolled about 23,000 participants, with some already receiving the second dose of the vaccine.

Pfizer “should be able to have enough events to say whether the product works or not” by the end of October, Bourla said Thursday in remarks to the International Federation of Pharmaceutical Manufacturers and Associations.

The people who make that decision are on the Security and Data Monitoring Board. That’s an independent group of experts, separate from the company that makes the vaccine, separate from the doctors who conduct clinical trials, and separate from the federal government, who can look at the data early.

“They are there to protect the safety and define the accuracy of the vaccine,” Corey said.

If they see a clear sign that the vaccine is not safe, for example, if many people have severe reactions or if the people who receive the vaccine are more likely to become infected, they can stop the trial. They can also stop the trial if they see that the vaccine doesn’t really protect people – for example, if as many people who get the actual vaccine get infected as those who get a placebo.

And they can stop the trial if it appears that the vaccine is working better than expected. That’s why the CDC is asking states to be ready to distribute a vaccine in October or November, Health and Human Services Secretary Alex Azar told CBS This Morning.

“God forbid we get great data and come out of the Safety and Data Monitoring Board and the FDA determines that they meet their standards, and we’re not ready for distribution,” said Azar. “We need to be prepared for all contingencies and that is why the CDC is doing this.”

Corey said he doubted anyone on the board would feel pressure to stop a trial and recommend an FDA review because of pressure, be it pressure. politics or simply the pressure of trying to end a pandemic that has killed 185,000 Americans.

They warn of risks of a vaccine without full trials 1:35

It’s not that they don’t understand responsibility. They all can read, ”Corey said.

Falsey doesn’t think so either.

“I don’t think the message is that we are going to look at the data in the middle of the test and if it looks good, we will accept it,” Falsey said. If a vaccine is accelerated, it will be because there is definitive evidence, she said.

Offit agrees. He said he trusts the FDA and the approval process. But not everyone does.

“The irony of this is that, by the end of the year, you could have a safe vaccine. But there is an administration that has not generated much confidence, “she said.

“We may have a safe and effective vaccine, but people still don’t trust it because they don’t trust the way the administration has handled science. That would be the ultimate irony.

Kaitlan Collins and Kevin Liptak contributed to this story

.